Tuesday Apr 15
Cubist Pharmaceuticals, Inc. To Announce First Quarter 2014 Financial ...
Cubist Pharmaceuticals, Inc. will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014.
Trending on the Topix Network
Wed Apr 09, 2014
Atlas Venture's newest stab at an antibiotics biotech comes out of stealth
Recent federal legislation designed to encourage the development of new antibiotics is partly responsible for the launch of one of Atlas Venture's newest biotechs.
Tue Apr 08, 2014
The Motley Fool
Pfizer Blockbuster Zyvox Under Attack
With several important revenue streams drying up, this one has become more important than ever to the drug company.
Fri Apr 04, 2014
The Motley Fool
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
In two unanimous votes, the FDA panels agreed on the safety and efficacy of Cubist's tedizolid and Durata's dalbavancin.
Thu Apr 03, 2014
The Zacks Analyst Blog Highlights: Gilead, MannKind, Cubist, Regeneron and Medicines Co
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Wed Apr 02, 2014
Durata Therapeutics: Gains Ahead
Durata Therapeutics is a biotech company focused on the development of novel antibiotics for acute infectious skin diseases.
Antibiotic R&D Gains Traction: A Mid-Cap Company Leads The Way
The industry leader in developing antibiotics against "superbugs" and other multidrug-resistant bacteria is not a Big Pharma corporation, but Cubist Pharmaceuticals, headquartered in Lexington, MA.
Tue Apr 01, 2014
FDA Advisors Back Two Antibiotics for ABSSSIs
The FDA's Anti-Infective Drugs Advisory Committee voted unanimously to recommend approval of two antibiotics for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus .
Cubist Pharmaceuticals Receives Buy Rating from Aegis
's stock had its "buy" rating reaffirmed by analysts at Aegis in a research report issued to clients and investors on Tuesday, Analyst RN reports.
Cubist Appoints Robert J. Perez to Board of Directors
Cubist today announced the appointment of Robert J. Perez to its Board of Directors.
Mon Mar 31, 2014
Cellceutix Reports 20 Percent Enrollment Completed In Phase 2b Trial...
Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure ... (more)
FDA Advisory Committee Recommends Approval of Cubist's SIVEXTROa
Cubist Pharmaceuticals has announced today that the FDA Anti-Infective Drugs Advisory Committee voted to recommend approval of Cubist's investigational antibiotic SIVEXTROa .
FDA Advisory Committee Unanimously Recommends Approval of Cubist's...
Cubist Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration Anti-Infective Drugs Advisory Committee voted to recommend approval of Cubist's investigational antibiotic SIVEXTRO .
FDA panel votes in favor of approval for Cubist's new MRSA drug
An advisory committee to the U.S. Food and Drug Administration voted unanimously in favor of approval for the newest antibiotic by Cubist Pharmaceuticals , according to a spokeswoman for the company.
FDA panel says Cubist anti-infective shows efficacy, safety
Cubist Pharmaceuticals Inc's anti-infective tedizolid for acute bacterial skin infections shows substantial evidence of safety and efficacy, an advisory panel to the U.S. Food and Drug Administration concluded on Monday.
Fri Mar 28, 2014
On Monday, Cubist will seek U.S. approval of a new MRSA drug
For the first time in eight years, executives from Cubist Pharmaceuticals will trek down to Silver Springs, Md., on Monday to take part in the high-stakes hearing required for approval of a new drug in the U.S. Representatives from the Lexington drug company will appear before an advisory board to the U.S. Food and Drug Administration to seek ... (more)
Thu Mar 27, 2014
Cantor Fitzgerald Increases Cubist Pharmaceuticals Price Target to $73.00
Cantor Fitzgerald's target price suggests a potential upside of 0.61% from the company's current price.
Thu Mar 20, 2014
A year after IPO, 'the world has changed' for Tetraphase
A year after going public, the head of Watertown-based Tetraphase says the investment world has become far more receptive to antibiotic biotech firms like his.
The Motley Fool
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate.